John A. Thompson
M.D., University of Alabama, 1979.
B.A., Davidson College, 1973.
My clinical research interests focus on the immunotherapy of cancer with cytokines and activated lymphocytes. A partial listing of trials currently under my direction include:
I serve on the National Comprehensive Cancer Network Clinical Guidelines Committees for Melanoma and Occult Primary, the Southwest Oncology Group Melanoma and Lymphoma committees, and the Cytokine Working Group. I am a member of the American Joint Committee on Cancer working group for staging of melanoma. I am the current Secretary-Treasurer of the Washington State Medical Oncology Society.
Alpha Omega Alpha, 1978
Recipient, Clinical Investigator Award (NCI), 1985-1988
American Association for Cancer Research
American Society of Clinical Oncology
Society for Biological Therapy
Southwest Oncology Group
Washington State Medical Oncology Society
1993-2004, Associate Professor, University of Washington, School of Medicine, Medicine, Oncology
1988-1993, Assistant Professor, University of Washington, Oncology
1985-1988, Acting Assistant Professor, University of Washington, Oncology
1982-1985, Fellow, University of Washington, Oncology
1982-1982, Chief Medical Resident, Providence Medical Center
1979-1982, Intern and Resident, University of Washington, Internal Medicine
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.. The Journal of experimental medicine.. 2016.
Major Changes in Systemic Therapy for Advanced Melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(5 Suppl):638-40.. 2016.
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016.
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(12):2855-2864.. 2016.
PD-1 Blockade in Melanoma: A Promising Start, but a Long Way to Go.. JAMA. 315(15):1573-5.. 2016.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.. The New England journal of medicine.. 2016.
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(4):450-73.. 2016.
Treatment options expanding for advanced melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(5 Suppl):673-5.. 2015.
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.. Investigational new drugs. 33(3):652-63.. 2015.
Systemic therapy of metastatic melanoma: on the road to cure.. Oncology (Williston Park, N.Y.). 29(2):126-35.. 2015.
Melanoma, version 4.2014.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5):621-9.. 2014.
Agents make "preferred list" in metastatic melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 12(5 Suppl):785-7.. 2014.
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma.. European journal of cancer (Oxford, England : 1990).. 2014.
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.. Cancer treatment reviews.. 2014.
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.. Journal for immunotherapy of cancer. 2:2.. 2014.
Ipilimumab administration in patients with advanced melanoma and hepatitis B and C.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(21):e370-2.. 2013.
Melanoma, version 2.2013: featured updates to the NCCN guidelines.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(4):395-407.. 2013.
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.. Proceedings of the National Academy of Sciences of the United States of America. 109(12):4592-7.. 2012.
Melanoma.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(3):366-400.. 2012.